非アルコール性脂肪肝炎治療市場規模、シェア、動向分析レポート：薬剤別、病期別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

非アルコール性脂肪肝炎治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の非アルコール性脂肪肝炎（NASH）治療市場規模は、2025～2030年にかけて28.1%のCAGRを記録し、2030年までに338億米ドルに達すると予測されています。

非アルコール性脂肪肝炎治療市場は、主にNovo Nordiskのオゼンピック、Interceptのオカリバ、Inventivaのラニフィブラノールなどの薬剤の発売によって牽引されています。

アンメットニーズ市場には、承認された治療がないこと、疾病負担が大きいこと、診断手順が複雑であることなどの要因により、大きなアンメットニーズが存在します。現在、市場はピオグリタゾンやビタミンEなどの適応外薬によって占められています。しかし、アンメット・オポチュニティに対処するため、主要市場参入企業はNASH治療のための新規治療を開発する研究開発活動に多額の投資を行っています。現在、50以上のパイプライン候補が存在します。

予測期間中に発売が予定されている後期段階のパイプライン候補には、Inventiva PharmaのLanifibranor、Intercept PharmaceuticalsのOveticholic acid、Galmed Pharmaceuticals Ltd.のAramchol、Novo Nordisk A/SのSemaglutide、Madrigal Pharmaceuticals, Inc.のResmetiromなどがあります。このうち、Intercept Pharmaceuticalのオベチコール酸（OCA）とMadrigal Pharmaceuticals, Inc.のレスメチロムは、最も注目されている医薬品であり、他のパイプライン候補よりも比較的早期に参入することが期待されています。

研究から、非アルコール性脂肪性肝炎は肥満や糖尿病と強く関連していることが明らかになっています。調査によると、NASH患者の約80％が肥満です。米国などでは、CDCによる最新の2021年の統計によると、肥満の有病率は42％と高いです。さらに、米国や日本などの国々は非アルコール性脂肪性肝炎の有病率が世界的に最も高く、これらの国々は肥満や糖尿病の負担も大きいです。このようなすべての要因が、予測期間を通じてNASH治療市場を活性化させると考えられます。

製薬大手による戦略的イニシアティブと、ファストトラック指定などの規制当局の支援施策が、市場の成長をさらに加速させると予想されます。2022年5月、Pfizer, Inc.のエルボガスタット/クレサコスタット併用療法はファストトラック指定を受けた。これは、非アルコール性脂肪性肝炎の治療として可能性のある薬剤の組み合わせの一つです。このような医薬品指定は、医薬品の臨床検査プロセスを後押しします。

肝生検は非アルコール性脂肪肝炎の診断のゴールドスタンダードです。この診断検査は侵襲的であるため、症候性の症例に限定され、その結果、NASHの診断率は世界平均で約20%です。非アルコール性脂肪肝炎の診断にバイオマーカーによる非侵襲的検査が利用できないことが、市場の成長を阻害すると予想されます。

非アルコール性脂肪肝炎治療市場レポートハイライト

• ビタミンEとピオグリタゾン（適応外）は、2024年の市場シェア100%を占める唯一の貢献者です。これは、市場で承認された医薬品が入手できないことに起因します。
• 小売・専門薬局セグメントは2024年に63.8%のシェアを占めました。小売・専門薬局は、NASHのような慢性疾患と相性がよく、患者は在宅医療環境にいることが多いです。
• 北米はNASH治療セグメント全体の売上高を支配しています。これは、疾患に対する認識が高まり、医療施設が充実し、他の地域よりも治療率が比較的高いことに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 非アルコール性脂肪肝炎治療市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 非アルコール性脂肪肝炎治療市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
• パイプライン分析

第4章 非アルコール性脂肪肝炎治療市場：薬剤別、推定・動向分析

• セグメントダッシュボード
• 世界の非アルコール性脂肪肝炎治療市場：薬剤変動分析
• 薬剤別、収益
• 気管支拡大薬
• オベチコール酸（OCA）
• ラニフィブラノール
• セマグルチド
• レスメチロム
• アラムチョル
• アラムチョル
• セニクリビロック
• その他

第5章 非アルコール性脂肪肝炎治療市場：病期別、推定・動向分析

• セグメントダッシュボード
• 世界の非アルコール性脂肪肝炎治療市場：病期変動分析
• 病期別、収益
• NASHステージF0
• NASHステージF1
• NASHステージF2
• NASHステージF3
• NASHステージF3

第6章 非アルコール性脂肪肝炎治療市場：流通チャネル別、推定・動向分析

• セグメントダッシュボード
• 世界の非アルコール性脂肪肝炎治療市場：流通チャネル変動分析
• 流通チャネル別、収益
• 病院薬局
• 小売・専門薬局
• その他の薬局

第7章 非アルコール性脂肪肝炎治療市場： 製品、用途、最終用途、地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要企業の市場シェア分析、2024年
  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Inventiva.
  • AbbVie Inc.
  • Galectin Therapeutics Inc.
  • Madrigal Pharmaceuticals Inc（Madrigal）.
  • NGM Biopharmaceuticals, Inc.
  • Novo Nordisk A/S
  • The Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 List of Secondary Sources
• Table 3 List of Abbreviation
• Table 4 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
• Table 5 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 6 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 7 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 8 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 9 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 10 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 11 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 12 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Disease Stage, 2018 - 2030 (USD Million)
• Table 13 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 14 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Drug, 2018 - 2030 (USD Million)
• Table 15 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Disease Stage, 2018 - 2030 (USD Million)
• Table 16 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 17 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
• Table 18 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 19 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 20 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 21 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 22 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 23 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 24 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 25 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 26 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 27 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 28 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 29 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 30 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 31 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 32 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 33 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 34 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 35 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 36 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 37 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 38 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 39 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 40 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 41 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 42 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 43 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 44 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 49 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 50 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 51 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 52 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 53 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 54 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 55 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 56 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 57 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 58 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 59 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 60 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 61 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 62 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 63 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 64 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 65 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 66 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 67 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
• Table 68 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 69 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 70 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 71 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 72 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 73 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 74 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 75 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 76 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 77 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
• Table 78 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 84 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 85 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 86 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 87 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 88 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 89 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
• Table 90 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
• Table 91 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
• Table 92 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Non-Alcoholic steatohepatitis (NASH) treatment market Segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Non-alcoholic steatohepatitis (NASH) treatment market snapshot
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Non-alcoholic steatohepatitis (NASH) treatment market driver impact
• Fig. 14 Non-alcoholic steatohepatitis (NASH) treatment market restraint impact
• Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 16 Industry Analysis - Porter's Five Forces
• Fig. 17 Strategy mapping
• Fig. 18 Non-alcoholic steatohepatitis (NASH) treatment market: Drug outlook and key takeaways
• Fig. 19 Non-alcoholic steatohepatitis (NASH) treatment market: Drug movement analysis & market share 2024 & 2030
• Fig. 20 Vitamin E and Pioglitazone non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Obeticholic Acid non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Lanifibranor non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Semaglutide non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Resmetirom non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Aramchol non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Cenicriviroc non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Other drugs non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Non-alcoholic steatohepatitis (NASH) treatment market: Disease stage outlook and key takeaways
• Fig. 29 Non-alcoholic steatohepatitis (NASH) treatment market: Disease stage movement analysis & market share 2024 & 2030
• Fig. 30 NASH F0 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 NASH F1 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 NASH F2 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 NASH F3 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 NASH F4 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Non-alcoholic steatohepatitis (NASH) treatment market: Distribution channel outlook and key takeaways
• Fig. 36 Non-alcoholic steatohepatitis (NASH) treatment market: Distribution channel movement analysis & market share 2024 & 2030
• Fig. 37 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Retail and specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market: Regional movement analysis
• Fig. 41 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market: Regional outlook and key takeaways
• Fig. 42 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market share and leading players
• Fig. 43 North America, by country
• Fig. 44 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 U.S. key country dynamics
• Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Canada key country dynamics
• Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Mexico key country dynamics
• Fig. 50 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 UK key country dynamics
• Fig. 53 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Germany key country dynamics
• Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 France key country dynamics
• Fig. 57 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Italy key country dynamics
• Fig. 59 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Spain key country dynamics
• Fig. 61 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Denmark key country dynamics
• Fig. 63 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Sweden key country dynamics
• Fig. 65 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Norway key country dynamics
• Fig. 67 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 China key country dynamics
• Fig. 70 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Japan key country dynamics
• Fig. 72 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 India key country dynamics
• Fig. 74 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Thailand key country dynamics
• Fig. 76 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 South Korea key country dynamics
• Fig. 78 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Australia key country dynamics
• Fig. 80 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Brazil key country dynamics
• Fig. 83 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Argentina key country dynamics
• Fig. 85 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 South Africa key country dynamics
• Fig. 88 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Saudi Arabia key country dynamics
• Fig. 90 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 91 UAE key country dynamics
• Fig. 92 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Kuwait key country dynamics
• Fig. 94 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Market share Analysis of key market players, 2024

Non-alcoholic Steatohepatitis Treatment Market Growth & Trends:

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 33.80 billion by 2030, registering a CAGR of 28.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights:

• Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with a 100% share of the market in 2024. This can be attributed to the unavailability of approved drugs in the market
• The retail and specialty pharmacies segment held a share of 63.8% in 2024. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
• North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Disease Stage
  • 1.2.3. Distribution channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug and disease stage outlook
  • 2.2.2. Distribution channel outlook
• 2.3. Competitive Insights

Chapter 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of Non-Alcoholic Steatohepatitis (NASH) disease
    • 3.2.1.2. Rising awareness about disease
    • 3.2.1.3. Robust product pipeline and rising R&D
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Stringent regulations
• 3.3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pipeline Analysis

Chapter 4. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Movement Analysis
• 4.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Drug, Revenue (USD Million)
• 4.4. Bronchodilators
  • 4.4.1. Vitamin E and Pioglitazone market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Obeticholic Acid (OCA)
  • 4.5.1. Obeticholic Acid (OCA) market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Lanifibranor
  • 4.6.1. Lanifibranor market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Semaglutide
  • 4.7.1. Semaglutide market estimates and forecasts 2018 - 2030 (USD Million)
• 4.8. Resmetirom
  • 4.8.1. Resmetirom market estimates and forecasts 2018 - 2030 (USD Million)
• 4.9. Aramchol
  • 4.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
• 4.10. Aramchol
  • 4.10.1. Aramchol market estimates and forecasts 2018 - 2030 (USD Million)
• 4.11. Cenicriviroc
  • 4.11.1. Cenicriviroc market estimates and forecasts 2018 - 2030 (USD Million)
• 4.12. Other Drugs
  • 4.12.1. Other drugs market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Movement Analysis
• 5.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Disease Stage, Revenue (USD Million)
• 5.4. NASH Stage F0
  • 5.4.1. NASH stage F0 market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. NASH Stage F1
  • 5.5.1. NASH stage F1 market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. NASH Stage F2
  • 5.6.1. NASH stage F2 market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. NASH Stage F3
  • 5.7.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
• 5.8. NASH Stage F3
  • 5.8.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Movement Analysis
• 6.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospitals Pharmacies
  • 6.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Retail and Specialty Pharmacies
  • 6.5.1. Retail and Specialty Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Other Pharmacies
  • 6.6.1. Other pharmacies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Intercept Pharmaceuticals, Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Galmed Pharmaceuticals Ltd.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Inventiva.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. AbbVie Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Galectin Therapeutics Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Madrigal Pharmaceuticals Inc (Madrigal).
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. NGM Biopharmaceuticals, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Novo Nordisk A/S
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. The Bristol-Myers Squibb Company
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Gilead Sciences, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives